Comparative Pharmacology
Head-to-head clinical analysis: AMBODRYL versus HYDROXYZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBODRYL versus HYDROXYZINE HYDROCHLORIDE.
AMBODRYL vs HYDROXYZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine (H1-receptor antagonist) with anticholinergic and sedative properties.
Hydroxyzine hydrochloride is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors. It also possesses anticholinergic, antiemetic, and sedative properties. Its mechanism involves binding to H1 receptors in the gastrointestinal tract, uterus, blood vessels, and bronchial muscles, thereby inhibiting histamine-mediated effects.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed, up to a maximum of 80 mg/day.
25-100 mg orally or intramuscularly 3-4 times daily; maximum 600 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-15 hours in adults; prolonged to 20-30 hours in hepatic impairment.
Terminal elimination half-life is approximately 20-25 hours in adults. In elderly or hepatic impairment, may be prolonged. Clinical context: Achieves steady-state after ~4-5 days; detectable for >72 hours after cessation.
Primarily renal (70-80% as metabolites, 20-30% unchanged); biliary/fecal excretion accounts for 15-20%.
Primarily hepatic metabolism via CYP3A4 and CYP3A5; <1% excreted unchanged in urine. Renal elimination of metabolites (approx. 50-60% of total clearance), with minor fecal excretion (<10%).
Category C
Category A/B
Antihistamine
Antihistamine